These findings disclose an unrecognized mechanism for the role of S100A16 as a potential target for ALD and expose new insights into the action of other novel therapeutic targets for NAFLD to alleviate ALD progression. The gene discussed is S100A16; the disease is metabolic dysfunction-associated steatotic liver disease.